BioMarin Pharmaceuticals
BMRN
341 hedge funds and large institutions have $13.4B invested in BioMarin Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 58 funds opening new positions, 108 increasing their positions, 133 reducing their positions, and 27 closing their positions.
115% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 27
97% more call options, than puts
Call options by funds: $116M | Put options by funds: $59M
25% more capital invested
Capital invested by funds: $10.7B → $13.4B (+$2.68B)
22% more funds holding in top 10
Funds holding in top 10: 9 → 11 (+2)
8% more funds holding
Funds holding: 316 → 341 (+25)
19% less repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 133
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$120M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$112M |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
+$104M |
| 4 |
VAM
Visium Asset Management
New York
|
+$82.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$70.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$108M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$86.5M |
| 3 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
-$77.4M |
| 4 |
Alkeon Capital Management
New York
|
-$54.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$50M |
BMRN Hedge Fund Activity: Q4 2014 in Review
341 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2014, worth a combined $13.4B — up 25% from $10.7B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new BMRN positions and 27 closed out — a net gain of 31 holders — while 108 added to existing stakes and 133 trimmed.
The largest buyer was Victory Capital Management, opening a new position worth an estimated $120M. The largest seller was State Street, cutting an estimated $108M.
- 341 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2014, up from 316 in Q3 2014.
- Funds reported $13.4B of BioMarin Pharmaceuticals stock for Q4 2014, up 25% quarter-over-quarter.
- 58 funds opened new BioMarin Pharmaceuticals positions in Q4 2014 and 27 closed out, a net change of +31 holders.
- The largest BioMarin Pharmaceuticals buyer in Q4 2014 was Victory Capital Management, an estimated $120M added.
- The largest BioMarin Pharmaceuticals seller in Q4 2014 was State Street, an estimated $108M sold.
Based on aggregated 13F filings for Q4 2014.